Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Air National Guard units from across the country are in Hawaii for the latest iteration of Sentry Aloha, a large-scale exercise hosted by the Hawaii Air National Guard’s 154th Wing, which is the ...

Many nonprofits in low- and middle-income countries face a critical mismatch: urgent social problems demand rapid program iteration, yet organizations often wait years for externally-produced ...

Abstract: Moving Average Filters are used for digital signal processing applications, such as smoothing ECG signals by minimizing high-frequency noise. This work investigates the design and ...

According to @godofprompt, recursive prompting is an AI technique where system outputs are fed back in as inputs to refine solutions through multiple iterations (source: @godofprompt, Dec 16, 2025).

The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Recursion Pharmaceuticals merged with Exscientia, another AI-driven drug discovery company, positioning itself as a potential biotech innovator The company has partnerships with major pharmaceutical ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...